NASDAQ:VERU - Veru Stock Price, News, & Analysis

Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.

Veru (NASDAQ:VERU) Frequently Asked Questions

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) released its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.07. The business earned $5.50 million during the quarter, compared to analysts' expectations of $5.20 million. Veru had a negative net margin of 130.26% and a negative return on equity of 38.09%. View Veru's Earnings History.

When is Veru's next earnings date?

Veru is scheduled to release their next quarterly earnings announcement on Tuesday, January 1st 2019. View Earnings Estimates for Veru.

What price target have analysts set for VERU?

3 analysts have issued twelve-month target prices for Veru's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Veru's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 476.9% from the stock's current price. View Analyst Price Targets for Veru.

What is the consensus analysts' recommendation for Veru?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru.

What are Wall Street analysts saying about Veru stock?

Here are some recent quotes from research analysts about Veru stock:

• 1. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (10/17/2018)
• 2. Maxim Group analysts commented, "Veru announced the company was awarded 75% of the South Africa female condom tender, or a total of 120M female condoms over three years. We view this news as a significant positive, as it will continue to help offset the R&D burn associated with the urology pipeline, which is where we see the most significant value and upside in Veru." (8/27/2018)
• 3. HC Wainwright analysts commented, "Valuation methodology. Our price target is derived from a market value of the firm at $302M, which includes a discounted cash flow-based asset value of $313M for DRS, excluding $10.7M debt and using a 15% discount rate, 0% terminal growth rate and 60% probability of success for Tamsulosin DRS. Risks include, but are not limited to: (1) failure of FC2 or Tamsulosin DRS to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of Tamsulosin DRS in clinical trials; (3) clinical trial failures with other pipeline candidates; and (4) potential dilution risk." (8/15/2018)

Who are some of Veru's key competitors?

Some companies that are related to Veru include Neptune Wellness Solutions (NEPT), CareTech (CTH), Nuvectra (NVTR), AVEO Pharmaceuticals (AVEO), Paratek Pharmaceuticals (PRTK), Kadmon (KDMN), Fluidigm (FLDM), BIOFRONTERA AG/ADR (BFRA), Proteostasis Therapeutics (PTI), RTI Surgical (RTIX), Unum Therapeutics (UMRX), Celcuity (CELC), Adverum Biotechnologies (ADVM), Athersys (ATHX) and Pieris Pharmaceuticals (PIRS).

Who are Veru's key executives?

Veru's management team includes the folowing people:

• Dr. Mitchell S. Steiner, Pres, CEO & Director (Age 57)
• Mr. O. B. Parrish, Co-Founder & Vice Chairman (Age 85)
• Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 59)
• Dr. Harry Fisch, Chief Corp. Officer & Director (Age 59)
• Mr. Kevin J. Gilbert, Sr. VP of Corp. Devel. & Legal and Sec.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $1.30.

How big of a company is Veru?

Veru has a market capitalization of $75.19 million and generates $13.66 million in revenue each year. The company earns $-6,610,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Veru employs 175 workers across the globe.

What is Veru's official website?

The official website for Veru is http://www.veruhealthcare.com.

How can I contact Veru?

Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]